KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GSK) Short-Term Debt issuances (2017 - 2025)

Historic Short-Term Debt issuances for Gsk (GSK) over the last 15 years, with Q4 2025 value amounting to $710.2 million.

  • Gsk's Short-Term Debt issuances fell 3176.82% to $710.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.2 billion, marking a year-over-year increase of 34826.56%. This contributed to the annual value of $1.4 billion for FY2025, which is 23801.96% up from last year.
  • According to the latest figures from Q4 2025, Gsk's Short-Term Debt issuances is $710.2 million, which was down 3176.82% from -$116.0 million recorded in Q3 2025.
  • Gsk's Short-Term Debt issuances' 5-year high stood at $1.0 billion during Q4 2024, with a 5-year trough of -$1.5 billion in Q4 2021.
  • Moreover, its 4-year median value for Short-Term Debt issuances was $148.6 million (2025), whereas its average is $16.8 million.
  • Per our database at Business Quant, Gsk's Short-Term Debt issuances plummeted by 11594.54% in 2021 and then soared by 15185.36% in 2024.
  • Over the past 4 years, Gsk's Short-Term Debt issuances (Quarter) stood at -$1.5 billion in 2021, then skyrocketed by 126.87% to $413.3 million in 2023, then surged by 151.85% to $1.0 billion in 2024, then tumbled by 31.77% to $710.2 million in 2025.
  • Its last three reported values are $710.2 million in Q4 2025, -$116.0 million for Q3 2025, and $1.0 billion during Q4 2024.